Research programme: antibacterials - eXegenics

Drug Profile

Research programme: antibacterials - eXegenics

Alternative Names: Antibacterials research programme - eXegenics; EXEG 1706

Latest Information Update: 13 Jul 2007

Price : $50

At a glance

  • Originator eXegenics
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections; Tuberculosis

Most Recent Events

  • 13 Mar 2007 eXegenics has merged with Acuity Pharmaceuticals and Froptix Corporation forming Opko Health
  • 18 Aug 2003 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
  • 18 Aug 2003 Discontinued - Preclinical for Tuberculosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top